This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background and Objective While underlying pathophysiology linking obesity to brain health is not completely understood, white adipose tissue (WAT) is considered a key player. In obesity, WAT becomes dysregulated, showing hyperplasia, hypertrophy, and eventually inflammation. This disbalance leads to dysregulated secretion of adipokines influencing both (cardio)vascular and brain health. Within this study, we investigated the association between omental WAT (oWAT) and subcutaneous WAT (scWAT) with brain structure and perfusion and cognition in adults with severe obesity.
Methods Within the cross-sectional BARICO study, brain structure and perfusion and cognitive function were measured before bariatric surgery (BS) using MRI and cognitive assessments. During BS, oWAT and scWAT depots were collected and analyzed by histopathology. The number and diameter of adipocytes were quantified together with the amount of crown-like structures (CLS) as an indication of inflammation. Blood samples were collected to analyze adipokines and inflammatory markers. Neuroimaging outcomes included brain volumes, cortical thickness, white matter (WM) integrity, WM hyperintensities, cerebral blood flow using arterial spin labeling (ASL), and the ASL spatial coefficient of variation (sCoV), reflecting cerebrovascular health.
Results Seventy-one patients were included (mean age 45.1 ± 5.8 years; 83.1% women; mean body mass index 40.8 ± 3.8 kg/m2). scWAT showed more CLS (z = −2.72, p < 0.01, r = −0.24) and hypertrophy compared with oWAT (F(1,64) = 3.99, p < 0.05, η2 = 0.06). Adiponectin levels were inversely associated with the average diameter of scWAT (β = −0.31, 95% CI −0.54 to −0.08) and oWAT (β = −0.33, 95% CI −0.55 to −0.09). Furthermore, the adipocyte diameter in oWAT was positively associated with the sCoV in the parietal cortex (β = 0.33, 95% CI 0.10–0.60), and the number of adipocytes (per mm2) was positively associated with sCoV in the nucleus accumbens (NAcc) (β = 0.34, 95% CI 0.09–0.61). Cognitive function did not correlate with any WAT parameter or plasma marker. These associations were highly influenced by age and sex. sCoV in the NAcc was positively associated with fasting plasma glucose (β = 0.35, 95% CI 0.10–0.56).
Discussion scWAT and oWAT are different in morphology and in their relationship with plasma markers and cerebrovascular health. Although scWAT showed more CLS and hypertrophy, scWAT was not associated with brain readouts. This study showed, however, important relationships between oWAT morphology and cerebrovascular health in obesity.
Trial Registration Information Trial Registration Number NTR7288 (trialregister.nl/trial/7090).
Glossary
- ASL=
- arterial spin labeling;
- ATT=
- arterial transit time;
- BMI=
- body mass index;
- BS=
- bariatric surgery;
- CBF=
- cerebral blood flow;
- COWAT=
- Controlled Word Association Test;
- CLS=
- crown-like structure;
- CRP=
- C-reactive protein;
- DWI=
- diffusion-weighted imaging;
- ELISAs=
- enzyme-linked immunosorbent assays;
- FPG=
- fasting plasma glucose;
- FLAIR=
- fluid-attenuated inversion recovery;
- GM=
- gray matter;
- HbA1c=
- hemoglobin A1c;
- ICV=
- intracranial volume;
- IQR=
- interquartile range;
- IL-6=
- interleukin-6;
- MoCA=
- Montreal Cognitive Assessment;
- MSMD=
- mean skeletonized mean diffusivity;
- nAcc=
- nucleus accumbens;
- ns=
- not significant;
- oWAT=
- omental WAT;
- ROI=
- region of interest;
- sCoV=
- spatial coefficient of variation;
- scWAT=
- Subcutaneous WAT;
- SAA=
- serum amyloid A;
- SIMOA=
- single-molecule array;
- TE=
- echo time;
- TI=
- inversion time;
- TR=
- repetition time;
- TAP=
- Test of Attentional Performance;
- TNF-α=
- tumor necrosis factor alpha;
- vWAT=
- visceral WAT;
- WAT=
- white adipose tissue;
- WC=
- waist circumference;
- WM=
- white matter;
- WMH=
- white matter hyperintensity
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
↵* The authors contributed equally to this work as first authors.
↵† These authors contributed equally to this work as senior authors.
Submitted and externally peer reviewed. The handling editor was Linda Hershey, MD, PhD, FAAN.
- Received April 22, 2022.
- Accepted in final form September 23, 2022.
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience
Dr. Henry J. Kaminski and Dr. Sarah Wright